[1] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023,77(5):1797-1835.
[2] Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options[J]. Cardiovasc Res, 2023,119(9):1787-1798.
[3] Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2[J]. Cell, 1998,92(4):441-450.
[4] Tajan M, de Rocca Serra A, Valet P, et al. SHP2 sails from physiology to pathology[J]. Eur J Med Genet, 2015,58(10):509-525.
[5] Sodir N M, Pathria G, Adamkewicz J I, et al. SHP2: a pleiotropic target at the interface of cancer and its microenvironment[J]. Cancer Discov, 2023,13(11):2339-2355.
[6] Shen D, Chen W, Zhu J, et al. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers[J]. Eur J Med Chem, 2020,190:112117.
[7] Yue X, Han T, Hao W, et al. SHP2 knockdown ameliorates liver insulin resistance by activating IRS-2 phosphorylation through the AKT and ERK1/2 signaling pathways[J]. FEBS Open Bio, 2020,10(12):2578-2587.
[8] Song Y, Wang S, Zhao M, et al. Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy[J]. J Med Chem, 2022,65(4):3066-3079.
[9] Tsutsumi R, Masoudi M, Takahashi A, et al. YAP and TAZ, hippo signaling targets, act as a rheostat for nuclear SHP2 function[J]. Dev Cell, 2013,26(6):658-665.
[10] Guo W, Liu W, Chen Z, et al. Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis[J]. Nat Commun, 2017,8(1):2168.
[11] Luo X, Liao R, Hanley K L, et al. Dual Shp2 and pten deficiencies promote non-alcoholic steatohepatitis and genesis of liver tumor-initiating cells[J]. Cell Rep, 2016,17(11):2979-2993.
[12] Zhang X, Zhang Y, Tao B, et al. Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis[J]. FASEB J, 2012,26(6):2338-2350.
[13] Juanola O, Martínez-López S, Francés R, et al. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors[J]. Int J Environ Res Public Health, 2021,18(10):5227.
[14] Kirichenko T V, Markina Y V, Bogatyreva A I, et al. The role of adipokines in inflammatory mechanisms of obesity[J]. Int J Mol Sci, 2022,23(23):14982.
[15] Mu C, Wang S, Wang Z, et al. Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease[J]. Ann Hepatol, 2025,30(1):101774.
[16] Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease[J]. Nutrients, 2013,5(5):1544-1560.
[17] Hall C, Yu H, Choi E. Insulin receptor endocytosis in the pathophysiology of insulin resistance[J]. Exp Mol Med, 2020,52(6):911-920.
[18] Matsuo K, Delibegovic M, Matsuo I, et al. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2[J]. J Biol Chem, 2010,285(51):39750-39758.
[19] Nagata N, Matsuo K, Bettaieb A, et al. Hepatic Src homology phosphatase 2 regulates energy balance in mice[J]. Endocrinology, 2012,153(7):3158-3169.
[20] Liu W, Yin Y, Wang M, et al. Disrupting phosphatase SHP2 in macrophages protects mice from high-fat diet-induced hepatic steatosis and insulin resistance by elevating IL-18 levels[J]. J Biol Chem, 2020,295(31):10842-10856.
[21] Paccoud R, Saint-Laurent C, Piccolo E, et al. SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations[J]. Sci Transl Med, 2021,13(591):eabe2587.
[22] Arroyave-Ospina J C, Wu Z, Geng Y, et al. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy[J]. Antioxidants (Basel), 2021,10(2):174.
[23] Kohli R, Pan X, Malladi P, et al. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway[J]. J Biol Chem, 2007,282(29):21327-21336.
[24] Ma Y, Lee G, Heo S Y, et al. Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease[J]. Antioxidants (Basel), 2021,11(1):91.
[25] Karampitsakos T, Galaris A, Barbayianni I, et al. SH2 domain-containing phosphatase-SHP2 attenuates fibrotic responses through negative regulation of mitochondrial metabolism in lung fibroblasts[J]. Diagnostics (Basel), 2023,13(6):1166.
[26] He Z, Zhu H H, Bauler T J, et al. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase[J]. Proc Natl Acad Sci U S A, 2013,110(1):E79-E88.
[27] Ferré P, Phan F, Foufelle F. SREBP-1c and lipogenesis in the liver: an update1[J]. Biochem J, 2021,478(20):3723-3739.
[28] Cheng C, Liu X H, He J, et al. Apolipoprotein A4 restricts diet-induced hepatic steatosis via SREBF1-mediated lipogenesis and enhances IRS-PI3K-Akt signaling[J]. Mol Nutr Food Res, 2022,66(18):e2101034.
[29] Gosis B S, Wada S, Thorsheim C, et al. Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1[J]. Science, 2022,376(6590):eabf8271.
[30] Katsarou A, Moustakas I I, Pyrina I, et al. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2020,26(17):1993-2011.
[31] Han X, Wei J, Zheng R, et al. Macrophage SHP2 deficiency alleviates diabetic nephropathy via suppression of MAPK/NF-κB-dependent inflammation[J]. Diabetes, 2024,73(5):780-796.
[32] Fiebelkow J, Guendel A, Guendel B, et al. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling[J]. Cell Commun Signal, 2021,19(1):94.
[33] Du L, Ji Y, Xin B, et al. Shp2 deficiency in Kupffer cells and hepatocytes aggravates hepatocarcinogenesis by recruiting non-Kupffer macrophages[J]. Cell Mol Gastroenterol Hepatol, 2023,15(6):1351-1369.
[34] Xu F, Liu C, Zhou D, et al. TGF-β/SMAD pathway and its regulation in hepatic fibrosis[J]. J Histochem Cytochem, 2016,64(3):157-167.
[35] Hu H H, Chen D Q, Wang Y N, et al. New insights into TGF-β/Smad signaling in tissue fibrosis[J]. Chem Biol Interact, 2018,292:76-83.
[36] Kang H J, Chung D H, Sung C O, et al. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development[J]. Oncotarget, 2017,8(16):27263-27276.
[37] Liu J J, Li Y, Chen W S, et al. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET[J]. J Hepatol, 2018,69(1):79-88.
[38] Chen W S, Liang Y, Zong M, et al. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment[J]. Cell Rep, 2021,37(6):109974.
[39] Liu J J, Xin B, Du L, et al. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity[J]. Hepatology, 2023,77(5):1512-1526.
[40] He S, Tang S. WNT/β-catenin signaling in the development of liver cancers[J]. Biomed Pharmacother, 2020,132:110851.
[41] Svinka J, Mikulits W, Eferl R. STAT3 in hepatocellular carcinoma: new perspectives[J]. Hepat Oncol, 2014,1(1):107-120.
[42] Watkins R D, Buckarma E H, Tomlinson J L, et al. SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy models[J]. JCI Insight, 2022,7(15):e159930.
[43] Yuan X, Yang L, Gao T, et al. YinChen WuLing powder attenuates non-alcoholic steatohepatitis through the inhibition of the SHP2/PI3K/NLRP3 pathway[J]. Front Pharmacol, 2024,15:1423903.
[44] Gao Q, Lu Y, Zhou W. Specific knockout of notch-1 attenuates non-alcoholic fatty liver disease by promoting SHP2 phosphorylation[J]. Aging (Albany NY), 2023,15(23):14323-14332. |
